Distribution | Full List | Categories |
by Country | by Vaccine |
PEOPLE VACCINATED | LAST 7 DAYS | |||||
countries over 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
Israel |
61.3% 5,307,975 |
56.8% 4,916,946 |
0.6% | 1.1% |
1.8% 151k |
|
Moderna, Pfizer/BioNTech | ||||||
United Kingdom |
47.0% 31,903,366 |
9.6% 6,541,174 |
0.9% | 2.3% |
3.2% 2,167k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Chile |
38.1% 7,284,213 |
23.5% 4,494,062 |
1.8% | 3.4% |
5.2% 990k |
|
Pfizer/BioNTech, Sinovac | ||||||
United Arab Emirates |
35.2% 3,480,415 |
22.1% 2,187,849 |
4.4% 432k |
|||
Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
United States |
34.6% 114,436,039 |
20.6% 68,202,458 |
3.8% | 3.1% |
6.4% 21,231k |
|
Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
Bahrain |
32.8% 557,298 |
21.3% 361,924 |
2.0% | 6.0% |
8.0% 137k |
|
Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
Hungary |
28.6% 2,760,938 |
12.1% 1,171,475 |
5.4% | 2.9% |
8.3% 806k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
Serbia |
24.6% 1,677,268 |
17.0% 1,158,744 |
3.2% | 1.4% |
4.6% 314k |
|
Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
Uruguay |
23.3% 808,486 |
5.5% 189,626 |
3.0% | 3.5% |
6.5% 226k |
|
Pfizer/BioNTech, Sinovac | ||||||
Singapore |
19.3% 1,131,658 |
9.2% 535,864 |
2.8% | 2.4% |
5.2% 305k |
|
Moderna, Pfizer/BioNTech | ||||||
Finland |
19.2% 1,066,860 |
1.7% 93,459 |
1.8% | 0.1% |
1.9% 105k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Canada |
18.0% 6,788,921 |
2.1% 780,400 |
3.8% | 0.2% |
4.0% 1,512k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Estonia |
17.8% 236,598 |
5.4% 72,035 |
2.5% | 0.6% |
3.1% 42k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Lithuania |
17.0% 463,596 |
6.9% 188,960 |
3.1% | 0.5% |
3.6% 97k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
France |
15.6% 10,148,039 |
5.3% 3,488,124 |
2.0% | 0.8% |
2.9% 1,865k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Austria |
15.5% 1,397,538 |
6.1% 549,588 |
1.8% | 0.9% |
2.7% 240k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Norway |
15.4% 835,970 |
5.4% 295,358 |
2.5% | 0.2% |
2.7% 146k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Spain |
15.3% 7,159,716 |
6.6% 3,072,109 |
3.0% | 0.5% |
3.5% 1,653k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Slovakia |
14.9% 811,508 |
5.1% 277,064 |
1.2% | 0.2% |
1.4% 77k |
|
Pfizer/BioNTech | ||||||
Slovenia |
14.8% 308,522 |
5.8% 120,067 |
1.3% | 0.0% |
1.3% 28k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Portugal |
14.8% 1,504,553 |
6.0% 613,485 |
2.0% | 0.6% |
2.6% 265k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Germany |
14.6% 12,204,176 |
5.8% 4,831,522 |
2.5% | 0.6% |
3.2% 2,661k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Belgium |
14.5% 1,677,523 |
5.2% 605,395 |
1.9% | 0.4% |
2.2% 259k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Denmark |
14.4% 835,271 |
7.4% 431,805 |
1.5% | 0.6% |
2.1% 122k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Italy |
14.4% 8,697,556 |
6.3% 3,812,342 |
2.0% | 0.7% |
2.8% 1,662k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Ireland |
13.8% 679,844 |
5.7% 282,043 |
1.5% | 0.9% |
2.5% 121k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Poland |
13.6% 5,167,241 |
5.5% 2,096,185 |
2.0% | 0.1% |
2.1% 801k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Sweden |
13.4% 1,355,828 |
5.6% 568,944 |
1.6% | 0.6% |
2.2% 226k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Greece |
13.4% 1,394,013 |
6.9% 720,209 |
2.5% | 0.8% |
3.2% 337k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Turkey |
12.8% 10,777,451 |
8.9% 7,542,933 |
1.7% | 0.6% |
2.4% 2,003k |
|
Pfizer/BioNTech, Sinovac | ||||||
Czechia |
12.6% 1,344,526 |
6.5% 692,274 |
1.1% | 1.2% |
2.3% 247k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Morocco |
12.1% 4,449,047 |
11.1% 4,103,257 |
0.3% | 0.7% |
1.0% 381k |
|
Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
Netherlands |
12.0% 2,057,562 |
4.7% 806,424 |
2.2% | 0.7% |
2.8% 485k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Romania |
11.5% 2,206,254 |
6.9% 1,319,863 |
0.9% | 1.1% |
2.0% 380k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Croatia |
10.7% 440,890 |
2.5% 102,546 |
0.9% | 0.2% |
1.1% 45k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Argentina |
9.4% 4,244,964 |
1.6% 711,059 |
1.8% | 0.1% |
1.8% 833k |
|
Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
Brazil |
9.4% 19,886,870 |
2.8% 5,848,444 |
1.8% | 0.6% |
2.4% 5,102k |
|
Oxford/AstraZeneca, Sinovac | ||||||
Dominican Republic |
9.2% 1,000,000 |
0.9% 101,528 |
1.4% | 0.7% |
2.2% 235k |
|
Oxford/AstraZeneca, Sinovac | ||||||
Latvia |
7.9% 149,157 |
1.4% 26,243 |
1.4% | 0.1% |
1.5% 28k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Kuwait |
7.5% 322,000 |
0.9% 38,000 |
1.9% 82k |
|||
Pfizer/BioNTech | ||||||
Mexico |
7.0% 8,978,215 |
1.3% 1,664,658 |
1.1% | 0.5% |
1.8% 2,340k |
|
Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
Azerbaijan |
6.6% 672,503 |
3.9% 396,985 |
1.1% | 1.0% |
2.1% 213k |
|
Sinovac | ||||||
Bulgaria |
6.5% 454,711 |
1.6% 112,685 |
0.8% | 0.2% |
1.0% 69k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
India |
6.2% 85,763,852 |
0.9% 12,311,308 |
1.6% | 0.2% |
1.8% 25,021k |
|
Covaxin, Oxford/AstraZeneca | ||||||
Panama |
5.8% 251,518 |
3.6% 157,100 |
0.1% | 0.8% |
2.1% 92k |
|
Pfizer/BioNTech | ||||||
Costa Rica |
5.7% 291,368 |
4.2% 213,562 |
1.2% | 0.9% |
2.1% 106k |
|
Pfizer/BioNTech | ||||||
Russia |
5.7% 8,333,331 |
3.6% 5,295,548 |
0.7% | 0.5% |
1.3% 1,850k |
|
EpiVacCorona, Sputnik V | ||||||
Cambodia |
5.5% 913,171 |
1.6% 274,582 |
2.6% | 0.2% |
2.8% 467k |
|
Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
WORLD |
5.4% 419,975,023 |
2.1% 163,275,277 |
0.8% | 0.3% |
1.5% 113,116k |
|
Sri Lanka |
4.3% 925,082 |
0.0% |
0.0% 1k |
|||
Oxford/AstraZeneca | ||||||
Colombia |
4.3% 2,172,751 |
1.3% 640,077 |
0.4% | 0.6% |
1.0% 512k |
|
Pfizer/BioNTech, Sinovac | ||||||
Jordan |
4.0% 404,912 |
1.2% 119,621 |
0.9% | 0.1% |
1.0% 101k |
|
Pfizer/BioNTech, Sinopharm/Beijing | ||||||
Indonesia |
3.4% 9,374,089 |
1.7% 4,697,396 |
0.4% | 0.3% |
0.7% 1,845k |
|
Oxford/AstraZeneca, Sinovac | ||||||
Bangladesh |
3.4% 5,568,703 |
0.1% |
0.1% 198k |
|||
Oxford/AstraZeneca | ||||||
Oman |
3.0% 152,036 |
0.4% 19,019 |
0.6% |
0.6% 31k |
||
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
El Salvador |
2.8% 180,000 |
0.7% |
0.7% 47k |
|||
Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
Rwanda |
2.7% 348,926 |
0.2% |
0.2% 25k |
|||
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Palestine |
2.6% 131,394 |
0.2% 11,748 |
0.9% | 0.1% |
1.0% 50k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Lebanon |
2.5% 170,506 |
1.5% 101,873 |
0.5% | 0.2% |
0.7% 47k |
|
Pfizer/BioNTech | ||||||
Bolivia |
2.4% 282,801 |
1.2% 141,041 |
0.7% | 0.2% |
0.9% 104k |
|
Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
South Korea |
2.2% 1,148,060 |
0.1% 59,422 |
0.4% | 0.1% |
0.4% 228k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Ghana |
2.1% 647,380 |
0.2% |
0.2% 69k |
|||
Oxford/AstraZeneca | ||||||
Senegal |
2.0% 326,910 |
0.3% |
0.3% 52k |
|||
Sinopharm/Beijing | ||||||
Peru |
1.9% 625,762 |
1.1% 363,842 |
0.1% | 0.1% |
0.2% 67k |
|
Sinopharm/Beijing | ||||||
Malaysia |
1.7% 546,762 |
1.1% 346,270 |
0.2% | 0.4% |
0.6% 195k |
|
Pfizer/BioNTech, Sinovac | ||||||
New Zealand |
1.5% 71,013 |
0.4% 19,273 |
0.3% | 0.2% |
0.5% 26k |
|
Pfizer/BioNTech | ||||||
Moldova |
1.4% 57,561 |
0.3% |
0.3% 13k |
|||
Oxford/AstraZeneca | ||||||
Jamaica |
1.4% 41,901 |
0.3% |
0.3% 9k |
|||
Oxford/AstraZeneca | ||||||
Ecuador |
1.4% 244,159 |
0.6% 112,624 |
0.3% | 0.2% |
0.6% 98k |
|
Pfizer/BioNTech | ||||||
Zimbabwe |
1.0% 153,238 |
0.2% 26,179 |
0.5% | 0.1% |
0.6% 88k |
|
Sinopharm/Beijing | ||||||
North Macedonia |
1.0% 21,333 |
0.6% |
0.6% 13k |
|||
Pfizer/BioNTech | ||||||
Tunisia |
1.0% 119,919 |
0.0% 4,860 |
0.4% | 0.0% |
0.4% 50k |
|
Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
Japan |
0.9% 1,101,698 |
0.4% 490,819 |
0.2% | 0.2% |
0.4% 496k |
|
Pfizer/BioNTech | ||||||
Malawi |
0.9% 164,733 |
0.2% |
0.2% 42k |
|||
Oxford/AstraZeneca | ||||||
Ukraine |
0.9% 373,000 |
0.2% |
0.2% 86k |
|||
Oxford/AstraZeneca | ||||||
Philippines |
0.8% 872,213 |
0.1% 50,685 |
0.1% | 0.1% |
0.2% 184k |
|
Oxford/AstraZeneca, Sinovac | ||||||
Equatorial Guinea |
0.8% 11,090 |
0.2% 2,990 |
0.2% | 0.1% |
0.2% 3k |
|
Sinopharm/Beijing | ||||||
Guatemala |
0.7% 130,985 |
0.0% 1,626 |
0.1% | 0.0% |
0.1% 22k |
|
Moderna, Oxford/AstraZeneca | ||||||
Myanmar |
0.7% 380,000 |
0.5% |
0.5% 293k |
|||
Oxford/AstraZeneca | ||||||
Thailand |
0.7% 470,301 |
0.1% 67,079 |
0.4% | 0.0% |
0.4% 305k |
|
Oxford/AstraZeneca, Sinovac | ||||||
Paraguay |
0.6% 46,000 |
0.0% 2,684 |
0.0% | 0.0% |
0.1% 3k |
|
Sputnik V | ||||||
Kenya |
0.6% 340,121 |
0.3% |
0.3% 178k |
|||
Oxford/AstraZeneca | ||||||
Australia |
0.6% 159,294 |
1.0% 254k |
||||
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Laos |
0.6% 40,732 |
|||||
Sinopharm/Beijing, Sputnik V | ||||||
Botswana |
0.6% 12,945 |
|||||
Oxford/AstraZeneca | ||||||
Angola |
0.6% 181,578 |
0.1% |
0.1% 44k |
|||
Oxford/AstraZeneca | ||||||
Honduras |
0.5% 52,772 |
0.1% |
0.1% 5k |
|||
Moderna, Oxford/AstraZeneca | ||||||
Gambia |
0.5% 12,674 |
0.2% |
0.2% 6k |
|||
Oxford/AstraZeneca | ||||||
Togo |
0.5% 42,092 |
|||||
Oxford/AstraZeneca | ||||||
South Africa |
0.5% 288,368 |
0.5% 288,368 |
0.0% | 0.0% |
0.0% 17k |
|
Johnson&Johnson | ||||||
Kazakhstan |
0.5% 90,748 |
0.1% 19,247 |
0.1% | 0.0% |
0.2% 28k |
|
Sputnik V | ||||||
Nigeria |
0.5% 964,387 |
0.2% |
0.2% 351k |
|||
Oxford/AstraZeneca | ||||||
Belarus |
0.4% 40,518 |
0.3% 26,100 |
0.1% | 0.1% |
0.2% 18k |
|
Sputnik V | ||||||
Sierra Leone |
0.4% 31,889 |
|||||
Oxford/AstraZeneca | ||||||
Georgia |
0.4% 15,693 |
0.2% |
0.2% 8k |
|||
Oxford/AstraZeneca | ||||||
Trinidad and Tobago |
0.3% 4,777 |
0.1% |
0.1% 1k |
|||
Oxford/AstraZeneca | ||||||
Venezuela |
0.3% 98,000 |
0.3% |
0.3% 84k |
|||
Sputnik V | ||||||
Afghanistan |
0.3% 120,000 |
0.1% |
0.1% 21k |
|||
Oxford/AstraZeneca | ||||||
Uganda |
0.3% 144,025 |
0.1% |
0.1% 54k |
|||
Oxford/AstraZeneca | ||||||
Mauritius |
0.3% 3,843 |
0.1% |
0.1% 2k |
|||
Oxford/AstraZeneca | ||||||
Iraq |
0.3% 103,006 |
0.2% |
0.2% 76k |
|||
Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
Eswatini |
0.2% 20,262 |
|||||
Oxford/AstraZeneca | ||||||
Albania |
0.2% 6,073 |
0.0% 655 |
3.0% 87k |
|||
Pfizer/BioNTech, Sinovac | ||||||
Cote d'Ivoire |
0.2% 53,071 |
0.0% |
0.0% 10k |
|||
Oxford/AstraZeneca | ||||||
Mozambique |
0.2% 57,305 |
0.0% |
0.0% 8k |
|||
Sinopharm/Beijing | ||||||
Iran |
0.2% 124,193 |
0.0% |
0.0% 27k |
|||
Sputnik V | ||||||
Sudan |
0.2% 63,837 |
|||||
Oxford/AstraZeneca | ||||||
Kosovo |
0.1% 2,500 |
|||||
Oxford/AstraZeneca | ||||||
Gabon |
0.1% 2,433 |
|||||
Sinopharm/Beijing | ||||||
Namibia |
0.1% 2,526 |
0.0% |
0.0% 1k |
|||
Sinopharm/Beijing | ||||||
Uzbekistan |
0.1% 35,000 |
|||||
Oxford/AstraZeneca | ||||||
Taiwan |
0.1% 20,075 |
0.0% |
0.0% 6k |
|||
Oxford/AstraZeneca | ||||||
Vietnam |
0.1% 58,037 |
0.0% |
0.0% 6k |
|||
Oxford/AstraZeneca | ||||||
Pakistan |
0.0% 72,882 |
0.1% 185k |
||||
Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
Mauritania |
0.0% 1,366 |
|||||
Sinopharm/Beijing | ||||||
Armenia |
0.0% 565 |
|||||
Sputnik V | ||||||
Kyrgyzstan |
0.0% 849 |
|||||
Sinopharm/Beijing | ||||||
Syria |
0.0% 2,500 |
|||||
Sputnik V | ||||||
Qatar |
*36.2% 1,041,632 |
6.1% 174k |
||||
Pfizer/BioNTech | ||||||
Mongolia |
*18.3% 599,132 |
8.4% 275k |
||||
Oxford/AstraZeneca | ||||||
Saudi Arabia |
*17.2% 5,982,107 |
3.6% 1,260k |
||||
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
China |
*11.2% 161,121,000 |
1.9% 27,320k |
||||
Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac | ||||||
Nepal |
*5.5% 1,600,000 |
1.1% 311k |
||||
Oxford/AstraZeneca | ||||||
Guinea |
*0.5% 67,863 |
0.1% 17k |
||||
Sputnik V | ||||||
Algeria |
*0.2% 75,000 |
0.1% 26k |
||||
Sputnik V | ||||||
Egypt |
*0.2% 148,987 |
0.0% 16k |
||||
Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
Mali |
0.0% 643 |
|||||
Oxford/AstraZeneca | ||||||
Papua New Guinea |
0.0% 250 |
|||||
Oxford/AstraZeneca |
PEOPLE VACCINATED | LAST 7 DAYS | |||||
countries below 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
Gibraltar |
97.6% 32,895 |
87.4% 29,446 |
5.8% | 8.1% |
13.9% 5k |
|
Pfizer/BioNTech | ||||||
Falkland Islands |
74.8% 2,605 |
49.3% 1,717 |
7.0% | 28.8% |
35.8% 1k |
|
Oxford/AstraZeneca | ||||||
Seychelles |
65.6% 64,508 |
40.1% 39,460 |
0.8% | 2.6% |
3.5% 3k |
|
Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
Bhutan |
61.3% 473,393 |
2.6% |
2.6% 20k |
|||
Oxford/AstraZeneca | ||||||
Isle of Man |
52.2% 44,343 |
18.1% 15,415 |
8.1% | 0.1% |
8.1% 7k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Maldives |
49.1% 265,235 |
2.8% 14,951 |
4.5% | 2.8% |
7.3% 39k |
|
Oxford/AstraZeneca | ||||||
Cayman Islands |
48.2% 31,661 |
37.4% 24,553 |
1.4% | 5.8% |
7.3% 5k |
|
Pfizer/BioNTech | ||||||
Jersey |
44.5% 44,981 |
22.5% 22,779 |
0.7% | 7.9% |
8.5% 9k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Guernsey |
44.1% 29,575 |
12.3% 8,254 |
4.4% | 0.4% |
5.1% 3k |
|
Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Bermuda |
38.2% 23,791 |
27.9% 17,361 |
1.9% | 2.8% |
4.7% 3k |
|
Pfizer/BioNTech | ||||||
Malta |
37.8% 167,130 |
14.8% 65,205 |
4.3% | 2.2% |
6.5% 29k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Anguilla |
35.7% 5,348 |
3.2% |
3.2% 0k |
|||
Oxford/AstraZeneca | ||||||
Turks and Caicos Islands |
33.4% 12,935 |
4.3% |
4.3% 2k |
|||
Pfizer/BioNTech | ||||||
Monaco |
29.9% 11,715 |
22.4% 8,795 |
2.5% | 0.6% |
3.1% 1k |
|
Pfizer/BioNTech | ||||||
Antigua and Barbuda |
27.0% 26,424 |
1.6% |
1.6% 2k |
|||
Oxford/AstraZeneca | ||||||
San Marino |
26.6% 9,021 |
19.6% 6,652 |
0.5% | 8.1% |
8.6% 3k |
|
Pfizer/BioNTech, Sputnik V | ||||||
Dominica |
24.7% 17,775 |
0.5% 337 |
2.4% | 0.5% |
2.8% 2k |
|
Oxford/AstraZeneca | ||||||
Montserrat |
22.2% 1,112 |
3.9% 194 |
4.4% | 3.1% |
7.5% 0k |
|
Oxford/AstraZeneca | ||||||
Barbados |
22.2% 63,738 |
0.0% |
0.0% 0k |
|||
Oxford/AstraZeneca | ||||||
Iceland |
17.2% 58,567 |
8.1% 27,801 |
2.1% | 0.9% |
3.0% 10k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Saint Kitts and Nevis |
16.1% 8,573 |
1.6% |
1.6% 1k |
|||
Oxford/AstraZeneca | ||||||
Faeroe Islands |
15.0% 7,345 |
8.5% 4,149 |
1.1% | 0.0% |
1.1% 1k |
|
Moderna, Pfizer/BioNTech | ||||||
Luxembourg |
14.6% 91,074 |
4.9% 30,879 |
2.4% | 1.2% |
3.6% 23k |
|
Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
Cyprus |
14.2% 124,165 |
5.8% 50,461 |
1.4% | 0.6% |
2.0% 18k |
|
Pfizer/BioNTech | ||||||
Saint Lucia |
11.0% 20,247 |
0.3% 1k |
||||
Oxford/AstraZeneca | ||||||
Andorra |
9.2% 7,098 |
1.6% 1,265 |
1.8% 1k |
|||
Pfizer/BioNTech | ||||||
Grenada |
8.7% 9,821 |
0.8% |
0.8% 1k |
|||
Oxford/AstraZeneca | ||||||
Greenland |
6.9% 3,927 |
2.1% 1,203 |
0.5% | 0.4% |
0.9% 1k |
|
Pfizer/BioNTech | ||||||
Suriname |
5.6% 32,614 |
0.8% |
0.8% 5k |
|||
Oxford/AstraZeneca | ||||||
Belize |
5.6% 22,067 |
1.0% |
1.0% 4k |
|||
Oxford/AstraZeneca | ||||||
Montenegro |
5.4% 34,172 |
0.9% 5,640 |
2.1% | 0.3% |
2.4% 15k |
|
Sinopharm/Beijing, Sputnik V | ||||||
Guyana |
5.1% 40,468 |
1.5% |
1.5% 12k |
|||
Oxford/AstraZeneca | ||||||
Sao Tome and Principe |
4.4% 9,724 |
2.6% |
2.6% 6k |
|||
Oxford/AstraZeneca | ||||||
Bahamas |
1.8% 7,000 |
|||||
Oxford/AstraZeneca | ||||||
Cape Verde |
0.4% 2,184 |
|||||
Oxford/AstraZeneca | ||||||
Solomon Islands |
0.3% 2,000 |
|||||
Oxford/AstraZeneca | ||||||
Brunei |
0.1% 340 |
|||||
Oxford/AstraZeneca | ||||||
Liechtenstein |
*18.1% 6,914 |
2.7% 1k |
||||
Moderna, Pfizer/BioNTech | ||||||
Saint Vincent and the Grenadines |
*9.5% 10,519 |
1.0% 1k |
||||
Oxford/AstraZeneca |